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ABSTRACT  
Background and objective  
People who inject drugs (PWID) account for over half of new HIV infections in Eastern 
Europe and central Asia, where opioids continue to be the dominant illicit drugs injected. 
Stimulants including amphetamines (ATS) have been associated with HIV infection risk 
in several settings. We sought to examine whether primary ATS injection was associated 
with greater HIV risk, compared to opioid injection in two European locales with 
significant HIV epidemics.  
Methods  
PWID in Kohtla-Järve and St. Petersburg were recruited using respondent-driven 
sampling in 2012-2013. Survey data on demographic characteristics, service use, injecting 
and sexual risk behaviours; and HIV-status (and HCV in Kohtla-Järve) were compared 
between primary opioid and ATS injectors using logistic regression models.  
Results   
Of 591 injectors recruited in Kohtla-Järve and 811 in St. Petersburg, 195 (33%) and 27 
(4%) primarily injected ATS in each city. In both cities, ATS injectors were younger than 
opioid injectors, initiated injection later, injected less frequently and were more likely to 
have been paid for sex. In both cities, PWID had high levels of multiple sex partners. In 
Kohtla-Järve, ATS-injectors had lower odds of back-loading and greater odds of polydrug 
use than opioid-injectors. In St. Petersburg, where over half of PWID reported unsafe 
sharing practices, ATS-injectors were less likely to report these practices. ATS-injection 
was negatively associated with being HIV positive in Kohtla-Järve (aOR=0.6; 95%CI: 0.5-
0.8) and St. Petersburg (aOR=0.3; 95%CI: 0.1-0.7). ATS-injection was negatively 
associated with HCV-reactivity in Kohtla-Järve (aOR=0.5; 95%CI: 0.3-0.6).  
Conclusions 
In both locations, primary ATS injection was associated with lower injecting risk 
behaviours, lower odds of HIV and being paid for sex compared to opioid injection. 
Interventions targeting the characteristics and needs of ATS injectors are needed to 
increase contact with services and reduce sexual and injecting risk. Harm reduction 
services, including sexual risk reduction, need to be expanded for all PWID in St. 
Petersburg. 
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INTRODUCTION 
People who inject drugs (PWID) were estimated to account for 51% of new human 
immunodeficiency virus (HIV-1) infections in Eastern Europe and central Asia in 2014, a 
region with the fastest growing HIV epidemic associated with injection drug use globally 
(UNAIDS, 2016; UNODC, 2016).   
Opioid injection has been the main driver of HIV epidemics in Estonia and the Russian 
Federation, where over half of PWID in Kohtla-Järve (Estonia) and St. Petersburg 
(Russian Federation) were seropositive in 2012 (El-Bassel, et al., 2013; Jolley, et al., 
2012; Uusküla, Raag, et al., 2015; Walsh, et al., 2013). Both cities are situated on the 
Baltic Sea, on the northern part of two major heroin trafficking corridors linking 
Afghanistan to the heroin markets of Western Europe; both have experienced HIV 
epidemics driven by transmission among PWID since the late 1990s (UNODC, 2012, 
2015b). Despite similar HIV prevalence, estimated incidence was higher in Kohtla-Järve 
(22/100 person-years, 2012) than in St. Petersburg (7.2/100 person-years, 2010), partly 
due to the higher proportion of young PWID in the Estonian city and to differences in the 
context and epidemic response, presented in Table 1. Evidence-based harm reduction 
interventions, including  needle and syringe programmes (NSP) and opiate substitution 
treatment (OST), were introduced in Kohtla-Järve in 2004 (Estonia Ministry of Health, 
2014; Mathers, et al., 2010) whereas in St Petersburg, OST remains illegal and clean 
needles and syringes are not endorsed by government and provided by a few non-
governmental organisations (Degenhardt, et al., 2014; EMCDDA, 2015). 
Most PWID injected heroin and illicitly-produced synthetic opioids, namely fentanyls in 
Kohtla-Järve (introduced into Estonia following a heroin shortage in 2000) and 
methadone in St Petersburg (Eritsyan, et al., 2013; Heimer, et al., 2015). Estonia has 
reported one of the highest prevalences of amphetamine type stimulant (ATS) use in 
Europe (EMCDDA, et al., 2012; UNODC, 2014) and ATS have emerged as a major 
secondary drug among PWID in Kohtla-Järve and St. Petersburg (EMCDDA, 2010; 
Grund, et al., 2009; UNODC, 2015a).  
ATS are psycho-stimulants that are relatively easy to synthesize and increasingly injected 
in settings previously dominated by opiates (Bao, et al., 2012; Booth, et al., 2008; Grund, 
et al., 2009). ATS have been associated with greater sexual risk, including multiple sex 
partners and unprotected sex, which may compound the risks of HIV acquisition among 
PWID (Baker, et al., 1994; Booth, et al., 2008; Darke, et al., 2008; Gleghorn, et al., 1998; 
Molitor, et al., 1999; Molitor, et al., 1998). ATS injection has also been associated with 
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more frequent injecting, needle/syringe sharing and HIV infection in settings where 
PWID also injected other drugs (Braine, et al., 2005; Hayashi, et al., 2011; Kozlov, et al., 
2006; Tavitian-Exley, et al., 2017) but not when stimulants were reported as main 
injection drug (Booth, et al., 2008; Kral, et al., 1998; Swe, et al., 2012; Talu, et al., 2010). 
Few studies have examined drug use patterns by main drug injected and potential 
associations with risk behaviours and HIV and HCV infection in Eastern European 
settings (Booth, et al., 2008; Harrell, et al., 2012; Talu, et al., 2010; Tavitian-Exley, et al., 
2015) and the relevance of ATS injection in shaping these epidemics remains unclear 
(EMCDDA, et al., 2011; EMCDDA, et al., 2014).  
Our aim is to assess whether primarily injecting ATS as compared to opioids (heroin, 
synthetic heroin or methadone) is associated with increased injecting and sexual risk 
behaviours and HIV status among PWID in Kohtla-Järve (Estonia) and St. Petersburg 
(Russian Federation), two East European locales with significant and epidemiologically 
similar HIV epidemics.  
METHODS 
Study population 
Integrated biological and behavioural surveys of HIV prevalence were conducted among 
PWID in Kohtla-Järve between May and July 2012, and in St. Petersburg from November 
2012 to June 2013. These surveys used comparable recruitment criteria and respondent-
driven sampling (RDS) survey methodology and have been reported on and described 
previously (Cepeda, et al., 2015; Dukhovlinova, et al., 2015; Heimer, et al., 2015; 
Tavitian-Exley, et al., 2017; Uusküla, Raag, et al., 2015). Briefly, RDS starts with a 
diverse sample of seeds (6 seeds in Kohtla-Järve and 12 seeds in different districts of St. 
Petersburg, subsequently increased to 16 to cover key districts and compensate for 
unproductive seeds). Seeds were selected through needle/syringe programmes (NSP) to 
represent a range of demographic and drug profiles; interviews and testing were 
conducted in fixed (Kohtla-Järve) and mobile clinics (St Petersburg). Each seed and 
subsequent participants were given an opportunity to recruit up to three PWID until a 
predetermined sample size was reached. Men and women aged 18 years or over, who had 
injected drugs in the past 30 days, lived in Kohtla-Järve or St. Petersburg and provided 
informed consent for the study were eligible. Eligibility was verified by the presence of 
injection marks and questions on injection practices before the start of the interview.   
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Measures 
Information on demographic and social factors, injection and sexual risk behaviours and 
access to harm reduction services were recorded by trained fieldworkers in a structured 
confidential interviewer-administered questionnaire, using standardised study items and 
questions from established survey instruments (e.g. WHO Drug Injecting study Phase II 
survey v2b) (Des Jarlais, et al., 2006; Uusküla, Raag, et al., 2015).  
HIV, HCV and HSV status 
HIV sero-status was assessed using an HIV Antigen/Antibody Combo Assay (ADVIA 
Centaur, Siemens Healthcare Diagnostics) and HIV I/II Score line assay confirmatory test 
(INNO LIA, Fujirebio Europe) in Kohtla-Järve; rapid oral HIV testing was conducted in St. 
Petersburg using OraQuick ADVANCE® Rapid HIV-1/2 Antibody Tests (OraSure 
Technologies Inc.) and confirmed at the City AIDS Centre (Uusküla, Raag, et al., 2015). In 
Kohtla-Järve only, HCV and Herpes Simplex Virus (HSV) reactivity were measured 
using commercially available kits for antibodies to HCV (Murex anti-HCV v 4.0) and 
HSV-2 (HSV-2 IgG ELISA, IBL International GmbH). 
The primary drug injected was categorised into mutually exclusive groups of primary 
ATS or primary opioid-injectors, based on the survey item main drug injected in the past 
4 weeks. Injectors reporting no or “other” primary drug were compared with the rest of the 
sample and examined in descriptive analysis (and excluded in regression modelling).  
Demographic and contextual variables 
Demographic and contextual variables included age, sex, ethnicity, highest level of 
education completed (basic education/secondary and above), main source of income, 
living arrangements (stable/unstable), past month contact with an NSP, past year drug 
treatment (opioid substitution in Kohtla-Järve; any drug treatment in St. Petersburg) and 
having needles or syringes confiscated by the police.  
Injecting and sexual risk behaviours 
The behavioural variables examined included injecting-risk (using a 30 day recall period), 
sexual-risk behaviours (using a 6 month recall period) and serological markers for HIV 
(and in Kohtla-Järve only, HCV and HSV). Injecting behaviours of interest were past 
month injecting frequency (≥daily injecting vs. <daily injecting), intensity of injection on 
the last day injected (≥ 2 injections/day vs. <2 injections/day), injecting with used 
needles/syringes (sharing), sharing drug paraphernalia, back-loading (filling a syringe 
from a used syringe) and polydrug use (injecting a main drug and at least one other drug 
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in the last month). Sexual risk behaviours included having a sex partner (regular or 
casual) who injected drugs, having been paid for sex (i.e. receiving money or drugs for 
sex ever), multiple sex partners (≥ 2 sex partners in last 6 months) and consistent condom 
use (i.e. always) with sex partners. The variable “any sex in the last six months” was used 
to exclude non-sexually active PWID.  
Statistical analyses  
Descriptive statistics are presented for Kohtla-Järve and St. Petersburg separately (RDS-
adjusted estimates, using the RDS-II estimator, are presented in supplementary material) 
(Volz, et al., 2008; Volz, et al., 2012; White, et al., 2015). 
Two sets of logistic regressions were performed. The first set examined the determinants 
of ATS- and opioid-injection. In the second set, we assessed whether ATS was associated 
with a) injecting-risk behaviours, b) sexual-risk behaviours, and c) HIV, HCV and HSV 
prevalence. For both sets of regressions, we generated univariate and multivariable 
estimates (Kirkwood, et al., 2003; UCLA Statistical Consulting Group, 2015). Results for 
the multivariable regressions were adjusted for age, sex, education, living arrangements 
and duration of injecting. In the second set of regressions, we additionally adjusted for 
contact with NSP and drug treatment. These variables were judged to be important 
potential confounders, based on published evidence and our conceptual framework 
(Supplementary material: Figure S.1) (Lemstra, et al., 2012; Marshall, et al., 2008; 
Marshall, et al., 2011; Poundstone, et al., 2004; Tavitian-Exley, 2016). Variables were 
examined for collinearity and omitted from the model if their variance inflation factor 
(VIF) was > 2.5. A complete case analysis was used and observations with missing values 
were omitted. Odds ratios (OR) with 95% confidence intervals (95%CI) were calculated 
while also adjusting for clustering of observations by recruitment seed (Kirkwood, et al., 
2003). Clusters were defined by a recruitment chain started by a given seed to account for 
the possibility that participants may be more likely to recruit other PWID with similar 
characteristics. This was achieved using the svy command in Stata (v.13.1) as in 
univariate analysis (Hosmer, 2000; Kirkwood, et al., 2003; StataCorp., 2013; UCLA 
Statistical Consulting Group, 2015). Sampling weights were not taken into account in the 
regressions as their use is often unwarranted for causal inference (Solon, et al., 2013). 
Ethics 
Ethical approval was obtained from the Ethics Review Board of the University of Tartu 
(Estonia), the Institutional Review Board at NGO Stellit in St. Petersburg (Russian 
Federation), and the Human Investigation Committee at Yale University (USA). 
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RESULTS 
Characteristics of study sample 
Our study included 591 PWID in Kohtla-Järve and 811 in St. Petersburg (Table 2; 
supplementary material Table S.1). In both cities, the majority of PWID were male, 
Russian-speaking or reporting stable living conditions (Table 2; Table S.1). However, 
more PWID in Kohtla-Järve were under the age of 30 and salaried or with a regular job 
than in St. Petersburg.  
The primary drug commonly injected by PWID in both cities was a synthetic opioid (i.e. 
illicitly-manufactured fentanyl congeners in Kohtla-Järve, heroin and methadone 
produced in illicit laboratories in St. Petersburg) while ATS was the second most common 
drug class. Opioids were the primary drug for 61% of PWID in Kohtla-Järve and 96% in 
St. Petersburg; ATS was the main drug for 33% in Kohtla-Järve and 4% in St. Petersburg 
(6% of PWID in Kohtla-Järve had another or no primary drug). 
More PWID had been in contact with a NSP in the past six months in Kohtla-Järve (82%) 
than in St. Petersburg (16%) and over half had ever received some form of attention for 
substance use disorder (Table 2). Substitution treatment was reported by 13% of PWID in 
Kohtla-Järve and detoxification by 11% in St. Petersburg in the past 12 months. Similar 
proportions of PWID had needles/syringes confiscated by the police in the last six months 
in both cities, but more PWID reported ever being incarcerated in Kohtla-Järve (55%) 
than in St. Petersburg (34%). 
The majority of PWID in both cities had injected for more than 5 years with a mean age at 
first injection of just under 19 years (Table S.1). Past-month injection risk behaviours 
were lower in Kohtla-Järve and up to nine times less frequent than in St. Petersburg. Past-
month polydrug use (injection of main and other drug) was equally widespread in both 
cities (47% and 41%). Fewer PWID in Kohtla-Järve had injected at least daily (24%) than 
in St. Petersburg (36%), shared needles and syringes (6% and 58%), filled from a used 
syringe (6% and 53%) or shared drug paraphernalia (7% and 68%). 
Over three quarters of PWID in both cities had had sexual intercourse in the last 6 months 
and over half had a sex partner who injected drugs (55% in Kohtla-Järve and 58% in St. 
Petersburg). Over a third of PWID had multiple sex partners (34% and 49%) and 7% in 
Kohtla-Järve and 4% in St. Petersburg respectively had ever been paid for sex. Close to 
half of PWID always used condoms with casual partners in Kohtla-Järve (58%) and St. 
Petersburg (48%). Due to the high non-response rate (>50%) for some sexual risk 
behaviours in Kohtla-Järve, results for this city were not shown, given the high likelihood 
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of bias; we only analysed the effect of ATS- or opioid-injection for those variables in St. 
Petersburg (Table S.1). More than half of PWID tested positive for HIV in Kohtla-Järve 
(61%) and in St. Petersburg (56%). HCV and HSV reactivity measured in Kohtla-Järve 
only, was 75% and 32%, respectively. 
Associations between primary ATS injection and injecting and sexual risk 
behaviours and serology in Kohtla-Järve 
Determinants of ATS injection 
Determinants of primary ATS injection are presented in Table 3. In Kohtla-Järve, ATS 
injectors were younger than opioid injectors with greater odds of being under 30 years of 
age (adjusted Odds Ratio (aOR) =2.1; 95%CI: 1.4-3.2) and of later injection initiation 
(aOR: 1.1; 95%CI: 1.0-1.4) than their opioid-injecting peers. The groups did not differ on 
other demographic characteristics. ATS injectors had lower odds of past-year drug 
treatment (aOR=0.5; 95%CI: 0.3-0.9), past-month contact with an NSP (aOR=0.2; 
95%CI: 0.2-0.6), having needles/syringes confiscated by the police (aOR=0.3; 95%CI: 
0.1-0.8) and incarceration (aOR=0.3; 95%CI: 0.2-0.5). They had higher odds of obtaining 
clean needles/syringes from a pharmacy than an NSP (aOR: 4.9 (95%CI: 3.5-6.9). 
Associations with injecting risk behaviours  
Primary ATS injection was associated with a number of injecting risk behaviours (Table 
4). ATS injectors were more likely to have injected for less than 5 years (aOR=3.5; 95% 
CI: 1.9-6.2) (Table 4). ATS injection was negatively associated with frequent injecting 
(aOR=0.3; 95%CI: 0.2-0.6), lifetime needle/syringe-sharing (aOR= 0.3; 95%CI: 0.2-0.5) 
and back-loading (aOR= 0.4; 95%CI: 0.2-0.8) and was positively associated with 
polydrug use (aOR=2.0; 95%CI: 1.1-3.5). Past-month unsafe sharing practices such as 
sharing needles/syringe and drug paraphernalia were generally lower among primary ATS 
injectors but differences did not reach statistical significance (Table 4). 
Associations with sexual risk behaviours 
One third of PWID reported multiple sex partners with no significant difference between 
primary ATS- and opioid-injectors; however ATS injectors had greater odds of ever being 
paid for sex (aOR=2.6; 95%CI: 1.2-5.7)(Table 5). 
Associations with HIV, HCV and HSV prevalence 
Primary ATS injectors in Kohtla-Järve had lower odds of testing positive for HIV 
(aOR=0.6; 95%CI: 0.5-0.8) and having antibodies to HCV (aOR=0.5; 95%CI: 0.3-0.6) in 
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multivariate analysis, compared to primary opioid injectors (Table 6). HSV antibody 
status was not associated with ATS injection. 
Associations between primary ATS injection and injecting and sexual risk 
behaviours and HIV in St. Petersburg 
Determinants of ATS injection 
In St. Petersburg, primary ATS injectors had higher odds of being under 30 years of age 
(aOR=6.8; 95%CI: 2.8-16.5), female (aOR=1.7; 95%CI: 0.7-4.1), of later initiation to 
injection (aOR: 1.3; 95%CI: 1.1-1.4) or having unstable living arrangements (aOR=2.2; 
95%CI: 1.0-4.6) than opioid injectors (Table 3). Contact with NSP and drug treatment 
were very low in St. Petersburg and did not differ between ATS- and opioid-injectors. 
However ATS injectors had greater odds of obtaining needles and syringes from sources 
other than an NSP (e.g. from friends, other PWID, a drug dealer or in the street) (aOR=35; 
95%CI: 2.7-472) and lower odds of having been incarcerated and having needles/syringes 
confiscated compared to opioid injectors.  
Associations with injecting risk behaviours 
Primary ATS injectors were more likely to report fewer than 5 years of injecting 
(aOR=8.3; 95%CI: 2.2-31.6)(Table 4). Several injecting risk behaviours were negatively 
associated with ATS injection. Primary ATS injectors had lower odds of daily or more 
frequent injecting (aOR=0.2; 95%CI: 0.1-0.9), injecting more than twice a day (aOR: 0.3; 
95%CI: 0.1-0.6), sharing needles and syringes (aOR=0.2; 95%CI: 0.1-0.6), filling a 
syringe from a used syringe (aOR=0.2; 95%CI: 0.1-0.5) and sharing drug paraphernalia 
(aOR=0.3; 95%CI: 0.1-0.6) than opioid injectors. Polydrug use was frequent among both 
ATS- and opioid-injectors but did not differ significantly between the two groups.  
Associations with sexual risk behaviours 
Almost half of PWID in the Russian city reported multiple sex partners, with no 
significant difference between ATS- and opioid-injectors (Table 5). In multivariate 
analysis, ATS injectors had greater odds of being paid for sex (aOR=5.2; 95%CI: 1.0-
27.0) and using condoms consistently with casual sex partners (aOR=8.0; 95%CI: 1.1-
60.0).  
Associations with HIV prevalence 
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Primary ATS injectors in St. Petersburg had lower odds of testing positive for HIV than 
PWID injecting opioid (aOR=0.3; 95%CI: 0.1-0.7)(Table 6). HCV and HSV serology 
were not collected in St. Petersburg. 
DISCUSSION 
We compared risk behaviours and HIV status among self-identified primary ATS-
injectors and opioid-injectors in two settings with severe epidemics of drug use and HIV. 
Our results suggest that, in both locations, PWID primarily injecting ATS consistently 
differed on demographic characteristics and reported less or equally risky injecting 
behaviours compared to those who mainly injected opioids. ATS injectors in both cities 
were younger but started injecting later than opiate injectors, were more likely to report 
less than 5 years’ injecting and generally at earlier stages in their drug injecting careers. 
The younger age and later onset of injecting among ATS injectors, suggested the 
emergence of a different group of PWID who may be at earlier stages of drug dependence 
and injecting less frequently than their opioid-injecting peers. 
In St. Petersburg, contact with NSPs was generally low and did not differ between the two 
groups; there primary ATS injectors were less likely to have injected with used 
needles/syringes, shared drug paraphernalia or back-loaded than opiate injectors.  
However in Kohtla-Järve, where harm reduction services are established, ATS injectors 
were significantly less likely than opiate injectors to have had contact with NSPs and 
reported similar prevalence of sharing needles/syringes or drug paraphernalia. They were 
also less likely to back-load than opiate injectors. That more opiate injectors were in 
contact with NSPs (and OST) in Kohtla-Järve may have contributed to reducing risky 
injecting behaviours in this group, thus “levelling” injecting risk between the two drug 
groups.  
Our findings are generally consistent with other studies, where self-reported primary ATS 
injection was associated with younger age and fewer years of injecting among PWID in 
Australia (Kaye, et al., 2000), the USA (Braine, et al., 2005), Canada (Fairbairn, et al., 
2007), Ukraine and elsewhere in Estonia (Booth, et al., 2008; Talu, et al., 2010) and 
where primary ATS injectors reported similar or lower frequency of injection (Booth, et 
al., 2008; Braine, et al., 2005; Darke, et al., 2008; Gleghorn, et al., 1998; Kaye, et al., 
2000; Maher, et al., 2007; Talu, et al., 2010) and similar frequency of needle and syringe-
sharing than opiate injectors (Gleghorn, et al., 1998; Kaye, et al., 2000; Talu, et al., 2010).  
That primary ATS injectors in our study reported lower or similar injecting risk 
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behaviours than opiate injectors contrasts with findings from studies where ATS injection 
was not defined as main drug and occurred in the presence of other injection drugs, 
including heroin (Braine, et al., 2005; Crofts, et al., 1997; Hayashi, et al., 2011; Kozlov, et 
al., 2006; Martin, et al., 2010; Tavitian-Exley, et al., 2017). Injecting risk behaviours and 
infection risk associated with ATS injection may therefore differ depending on whether 
PWID inject ATS primarily or inject ATS in addition to or in combination with, addictive 
opiates such as heroin; these underline the need for consistent definitions and regular 
monitoring of drugs and drug combinations among PWID.   
Both ATS-injectors and opioid-injectors in this study reported similarly high prevalence 
of sexual risk, including multiple sex partners. However primary ATS injectors were more 
likely to have ever been paid for sex. ATS may be used to increase energy, stamina, libido 
and to reduce social and sexual inhibition. Further, injection often occurs with peers or 
sexual partners, possibly generating more needle-sharing opportunities (Darke, et al., 
1995; Klee, 1993). Several other studies of PWID also found positive associations 
between ATS injection and multiple sex partners, unprotected sex and trading sex for 
money or drugs (Lorvick, et al., 2006; Molitor, et al., 1999).  The frequency of sexual risk 
in both cities and possible intersection with sex work highlight the potential for sexual 
transmission of HIV, and an unmet need to engage diverse PWID sub-groups with 
prevention and risk reduction messages emphasising sexual as well as injecting risks 
(Lorvick, et al., 2006; Molitor, et al., 1998; Rondinelli, et al., 2009).  
Finally, HIV prevalence and HCV in Kohtla-Järve; were lower among ATS- than opioid-
injectors, consistent with their shorter, cumulative exposure to risk resulting from younger 
age and later onset of injecting (Kozlov, et al., 2006; Martin, et al., 2010). These 
differences in HIV status remained after adjusting for factors such as injecting duration, 
suggesting that other determinants also play a role. Primary ATS injectors are 
nevertheless vulnerable to HIV acquisition as a result of their age (and gender in St. 
Petersburg), high prevalence of sexual risk behaviours and low contact with harm 
reduction services (i.e. NSP and drug substitution treatment in Kohtla-Järve). 
The propensity of ATS injectors in Kohtla-Järve to obtain clean needles and syringes 
from pharmacies rather than NSPs when the majority of PWID in the sample were in 
contact with harm reduction services, also suggests they were not being reached 
(Vorobjov, et al., 2009). Furthermore, the lower odds of substitution treatment among 
ATS injectors in Kohtla-Järve may be expected since methadone-based substitution 
treatment has shown to reduce injecting risk behaviours and HIV infection and to support 
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adherence to highly active anti-retroviral therapy (HAART) among opioid users. However 
no proven pharmacological treatment exists for ATS-dependent injectors (Ahamad, et al., 
2015; MacArthur, et al., 2012; World Health Organization, 2013). Where ATS use is 
prevalent, services that are tailored to the demographic characteristics and specific needs 
of ATS injectors and include psychosocial interventions, need to be integrated into harm 
reduction programmes (Mehrjerdi, et al., 2014; UNODC, 2010). The problem of ATS 
injection in these cities, and globally, requires effective low-threshold services able to 
engage injectors who are young and/or female, do not fit the drug use “profile” associated 
with heroin and neither seek nor desire contact with services focused on opioid injectors 
(Lorvick, et al., 2006; Pates, 2013; Shearer, et al., 2002; Vorobjov, et al., 2009). 
Moreover, while few studies have looked at the life course of drug use among primary 
ATS injectors, especially in resource-limited settings (Brecht, et al., 2008), longitudinal 
and qualitative research would help to understand how primary ATS-injection and 
associated behavioural risks evolve over time. Consistent and systematic drug (and 
polydrug) monitoring would also contribute to better understanding heterogeneity among 
PWID. 
Several limitations need to be acknowledged. First, our findings may only be 
generalizable to other PWID populations in Estonia or the Russian Federation. Second, 
obtaining standard probability samples of PWID populations is challenging, due to the 
hidden nature of this group, their stigmatised behaviours and the absence of a sampling 
frame. Although RDS surveys have demonstrated the ability to reach hidden population 
sub-groups, the representativeness of our samples cannot be verified (Abdul-Quader, et 
al., 2006; Heckathorn, 1997; Johnston, et al., 2010). Third, information on injecting and 
sexual risk behaviours was collected through self-reports and social desirability bias may 
affect the results. Self-reporting using interviewer-administered questionnaires has shown 
reliability in several studies and a 30-day period, as was used in this study, has shown to 
produce reliable recall on drug use and injecting behaviours among PWID (Darke, 1998; 
Des Jarlais, et al., 1999; Napper, et al., 2010). Additionally, the small number of ATS 
injectors in St. Petersburg resulted in wide confidence intervals that limited our analyses 
for this city. Finally, given the dynamic nature of drug use, high prevalence of polydrug 
use in this population and shorter recall, it is conceivable that misclassification may have 
occurred between ATS-and opioid-injectors thus leading to possible bias. However, non-
differential misclassification of the exposure generally biased the inferences towards the 
null and, if this is the case here, our results could be considered conservative (Dosemeci, 
et al., 1990; Kirkwood, et al., 2003).  
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The strengths of this study include its large sample size and comparisons of two Eastern 
European locations reporting a high prevalence of HIV and injection of different drug 
classes. Recruitment of two large and diverse PWID samples was facilitated by the use of 
RDS and reported according to the STROBE-RDS statement (Johnston, et al., 2016; 
White, et al., 2015). We systematically compared PWID injecting different drug classes, 
using consistent definitions, study methods and tested tools and we highlighted important 
differences between self-identified primary ATS- and opioid-injectors that are of 
relevance to policy and programmes.  
Primary ATS injectors reported lower or similar injecting risk behaviours, lower HIV 
prevalence and less engagement with services, than opioid injectors. Both groups had high 
levels of multiple sex partners but primary ATS injection was associated with paid sex, 
suggesting overlaps between injecting and sexual risk. Low threshold interventions (e.g. 
behavioural) and supplies targeting the needs of young stimulant injectors are needed to 
increase their contact with prevention services and reduce sexual risk behaviours. The 
coverage of harm reduction services, including sexual risk reduction, needs to be 
increased significantly in St. Petersburg for all PWID.  
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Table 1. HIV epidemic, context and response among people who inject drugs in Kohtla-Järve 
(Estonia) and St. Petersburg (Russia) 
Indicator Kohtla-Järve St. Petersburg 
HIV incidence 22 per 100 person-year (2012) (NIfHD, 2015; 
Uusküla, Des Jarlais, et al., 2015)  
All Estonia: 7.5 per 100 person-year (2011) 
(NIfHD, 2015; Uusküla, Des Jarlais, et al., 2015) 
14.5 per 100 person-year (2008) (Niccolai, et al., 
2011) 
7.2per 100 person-year (2010) (Kozlov, et al., 
2016) 
HIV Prevalence 63% (95%CI: 56%-67%) (Uusküla, Raag, et al., 2015) 59% (95%CI: 52%-59%) (Uusküla, Raag, et al., 2015) 
PWID population size estimate 2,000 (range: 700-2,500)
All Estonia: 5,362 (range: 3,906–9,837) 
(Uusküla, et al., 2013) 
83,120 (95%CI:77,320 -88,920) (Heimer, et al., 
2010) 
% of population who inject drugs 4.5% (2012) (Wu J, et al., under review) 5.5% (2008) (Heimer, et al., 2010) 
Needle/syringe services (start year) 2004 1996
Needle/syringe services (n, type) 5 outreach, 3 fixed NSP (NIfHD, 2016) 2 mobile, 2 fixed site services (2015) 
Clean syringes per PWID per year All Estonia:  
125 syringes/PWID per year (2011) 
n/a
Needle/syringes services provided by NGOs City AIDS centre (as of 2015), NGOs 
Drug substitution (start year) 2004 OST illegal 
Type of drug treatment Opiate substitution Detoxification only (21 days) 
Coverage (%, n and year) All Estonia: 15% of PWID (n=919, 
2014)(NIfHD, 2016)  
11% PWID registered, % in treatment n/a 
Drug treatment services provided by NGOs, clinics Centralized, in-patient 
Table 1: Reference population for Estonia aged 15-44 years old; for St Petersburg aged 20-45 years old. Data collection years are 
italicised. HIV= Human Immune deficiency virus. PWID people who inject drugs. CI=Confidence Interval. NSP= Needle and Syringe 
Programme. OST=Opiate Substitution treatment. NGO= Non-governmental organisation. N/a=not available.  
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Table 2. Characteristics of sample and by reported primary amphetamine injection in Kohtla-Järve (Estonia) and 
St. Petersburg (Russian Federation) 
 
Kohtla-Järve St. Petersburg 
CHARACTERISTICS 
DEMOGRAPHIC VARIABLES 
All(1) PWID 
Kohtla-Järve
N 
591
Primary  
amphetamine
(%)(1) 
n
195
All(1) PWID 
St. Petersburg
N 
811 
Primary  
amphetamine 
(%)(1) 
n 
27 
Sex   
Female 26% 155 29.7% 58 22% 180 48.2% 13 
Male 74% 434 70.3% 137 78% 631 51.9% 14 
Missing 2 0 0  0 
Age group   
< 30 years  50% 294 61.5%* 120 30% 241 74.1%* 20 
>= 30 years 50% 297 38.5% 75 70% 570 25.9% 7 
Missing 0 0 0  0 
Ethnicity   
Estonian 12% 66 12.3% 24 0% 0 0% 0 
Other 7% 43 5.1% 10 4% 36 3.7% 1 
Russian 81% 481 82.6% 161 96% 775 96.3% 26 
Missing 1 0 0  0 
Education completed   
Basic (9th grade)/vocational 80% 472 81.0% 158 58% 475 29.6%* 8 
Secondary (11th grade) 19% 116 19.0% 37 30% 243 51.9% 14 
Higher (St. Petersburg only) 1% 3 0% 0 12% 93 18.5% 5 
Missing 0 0 0  0 
Living arrangements   
Unstable (hostel, dormitory, shelter) 40% 238 39.5% 77 36% 292 51.9%* 14 
Stable (own or partner’s flat/house) 60% 352 60.5% 118 64% 519 48.2% 13 
Missing 1 0 0  0 
Main income source   
irregular/illicit (SP only)  3% 15 - - 16% 134 3.7% 1 
non-regular/dependant 33% 193 38.5% 74 39% 312 37.0% 10 
regular/salaried 64% 375 61.5% 118 45% 362 59.3% 16 
Missing 8 3 3  0 
CONTEXTUAL VARIABLES   
Lifetime drug treatment   
Ever had drug treatment 55% 324 32.8%* 64 72% 582 25.9%* 7 
Never in treatment 45% 267 67.2% 131 28% 229 74.1% 20 
Missing 0 0 0  0 
Drug/substitution treatment   
Yes (12 months) 13% 75 6.7%* 13 11% 86 14.8% 4 
No  87% 516 93.3% 182 89% 724 85.2% 23 
Missing 0 0 1  0 
NSP programme (4 weeks)    
Contact with NSP 82% 451 66.7%* 124 16% 119 3.7%* 1 
No contact with NSP 18% 102 33.3% 62 84% 645 96.3% 26 
Missing 38 9 47  0 
Source of clean needle/syringes   
Other (friend, dealer, street) 5% 27 66.7%* 124 4% 30 40.7%* 11 
Pharmacist/chemist 13% 75 26.3% 49 81% 615 55.6% 15 
NSP 82% 451 7.0% 13 16% 119 3.7% 1 
Missing 38 9 47  0 
Incarceration   
Ever in prison 55% 324 30.3%* 59 34% 274 7.4%* 2 
Never in prison 45% 267 69.7% 136 66% 537 92.6% 25 
Missing 0 0 0  0 
Needles/syringes confiscated   
Had N/S confiscated 31% 404 15.9%* 31 26% 212 0% 0 
No N/S confiscated 69% 184 84.1% 164 74% 599 100% 27 
Missing 3 0 0  0 
Table 2: (1) Column percentage. Crude estimates are presented for Kohtla-Järve and St. Petersburg; adjusted 
estimates using respondent driven sampling weights (RDS-II, Volz-Heckathorn) are shown in supplementary 
material as is the number of missing observations. NSP=Needle and syringe programme. HIV= Human Immune 
deficiency Virus. (2) Drug/substitution treatment in last 12 months refers to opiate drug substitution (OST) in 
Kohtla-Järve and to detoxification (non-OST) in St Petersburg. *Statistically significant result in comparisons of 
ATS- and opioid-injectors using Pearson's Chi-squared test for proportions (p-value <0.05) or Fisher's exact when 
expected cell count is <4.  
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Table 3. Predictors of primary ATS injection in Kohtla-Järve (Estonia) and St. Petersburg (Russian Federation) 
DEMOGRAPHIC CHARACTERISTICS Kohtla-Järve - ATS injectors (n=195) St. Petersburg - ATS injectors (n=27) 
 (reference: opioid injectors) OR(1)95% CI aOR(2)95%CI OR(1)95% CI aOR(2)95%CI 
Sex 
 
 
Female 1.3(0.9-1.9) 1.3 (0.9-1.6) 3.4 (1.0-11.5) 1.7 (0.7- 4.1) 
Male ref ref ref ref 
Age group  
< 30 years  2.0 (1.3-3.3) 2.1 (1.4-3.2) 7.3 (2.6-20.3) 6.8 (2.8-16.5) 
>= 30 years ref ref ref ref 
Ethnicity 
 
 
Estonian 1.2 (0.8-1.9) 1.1 (0.6-2.1) - - 
Other 0.6 (0.2-1.8) 0.6 (0.3-1.1) 0.8 (0.1-9.2) 0.8 (0.1-11.4) 
Russian ref ref. ref. 
Education completed 
 
 
Basic (9thgrade)/vocational 1.1 (0.6-1.8) 1.0 (0.6-1.7) 0.3 (0.05-1.7) 2.6 (1.2-6.7) 
Secondary (11th grade) ref ref 1.1 (0.4-3.2) 2.5 (0.7-9.6) 
Higher (St. Petersburg only) - - ref ref 
Living arrangements   
Unstable (hostel, dorm, shelter) 0.9 (0.6-1.4) 0.9 (0.6-1.2) 2.0 (0.9-4.1) 2.2 (1.0-4.6) 
Stable (own/partner home) ref ref ref ref 
Main income source  
irregular/illicit (SP only) - - 0.2 (0.02-1.6) 0.1 (0.05-1.5) 
non-regular/dependant 1.3 (0.9 -1.7) 1.0 (0.6 -1.5) 0.7 (0.4-1.5) 0.8 (0.4-1.5) 
regular/salaried ref. ref. ref ref 
Age at first injection  
Primary ATS/Opioid 1.1 (1.1-1.2) 1.1 (1.0-1.2) 1.1 (1.0-1.3) 1.3 (1.1-1.4) 
CONTEXTUAL VARIABLES     
Lifetime drug treatment   
Ever drug treatment 0.2 (0.2-0.3) 0.3 (0.2-0.5) 0.2 (0.1-0.6) 0.2 (0.1-0.5) 
Never in treatment ref ref ref ref 
Drug/substitution treatment  
Yes (12 months) 0.4(0.2-0.7) 0.5 (0.3-0.9) 1.5 (0.4-5.8) 1.9 (0.3-12.7) 
No  ref. ref ref ref 
NSP programme (4 weeks)   
Contact with NSP 0.2 (0.1-0.3) 0.2 (0.2-0.6) 0.2 (0.05-1.0) 0.4 (0.1-2.2) 
No contact with NSP ref ref ref ref 
Source of clean needle/syringes  
Other (friend, dealer, street) 2.4 (0.7-9.9) 2.0 (0.5-7.9) 67 (8.1-544) 35 (2.7-472) 
Pharmacist/chemist 6.0 (4.1-8.6) 4.9 (3.5-6.9) 2.9 (0.6-14.2) 1.8 (0.3-9.3) 
NSP ref ref ref ref 
Incarceration   
Ever in prison 0.2 (0.1-0.3) 0.3 (0.2-0.5) 0.2 (0.1-0.3) 0.2 (0.1-0.8) 
Never in prison ref ref ref ref 
Needles/syringes confiscated  
Had N/S confiscated 0.3 (0.1-0.9) 0.3 (0.1-0.8) - Too few obs. 
No N/S confiscated ref ref   
Table 3. (1) Odds ratio (OR) with 95% confidence intervals (95% CI) refer to primary Amphetamine-Type Stimulant (ATS) versus 
opioids (reference group is “primary opioid injectors”). (2) Multivariable model for ATS was adjusted for predictors: age, sex, 
education, duration of injecting (and living arrangements in St. Petersburg). Statistically significant results at the α< 0.05 are 
marked in bold. (3) Needle/syringe programme (NSP), drug treatment and needles/syringes confiscated were adjusted for in 
models where the outcome was injecting risk. (4) Drug/substitution treatment in last 12 months refers to opiate drug 
substitution (OST) in Kohtla-Järve and to detoxification (non-OST) in St Petersburg. 
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Table 4. Association between ATS injection and injecting risk behaviours (Kohtla-Järve, St. Petersburg) 
OUTCOMES: INJECTING RISK (3)  Kohtla-Järve – ATS injectors (n=195) St. Petersburg – ATS injectors (n=27) 
 (reference: opioid injectors) OR(1)95% CI aOR(2)95%CI OR(1)95% CI aOR(2)95%CI 
Duration of injecting 
 
 
≤ 5 years 6.1 (3.8-9.6) 3.5 (1.9-6.2) 14.7 (4.2-51) 8.3 (2.2-31.6)
> 5 years ref. ref ref. ref 
Frequency of injecting  
Daily or more 0.2 (0.1-0.5) 0.3 (0.2-0.6) 0.2 (0.1-1.0) 0.2 (0.1-0.9)
Less than daily  ref. ref. ref. ref. 
Ever shared needles/syringes  
Yes 0.2 (0.1-0.3) 0.3 (0.2-0.5) 0.05 (0.03-0.1) 0.1 (0.1-0.2)
No ref. ref. ref. ref. 
Injected w/used needles/syringes   
Yes 0.5 (0.1-1.6) 0.5 (0.2-1.5) 0.1 (0.05-0.3) 0.2 (0.1-0.6)
No ref. ref. ref. ref. 
Filled from working syringe (back-loaded)  
Yes 0.4 (0.2-1.2) 0.4 (0.2-0.8) 0.1 (0.1-0.3) 0.2 (0.1-0.5)
No ref. ref. ref. ref. 
Shared drug paraphernalia  
Yes 0.5 (0.2-1.3) 0.5 (0.3-1.2) 0.2 (0.1-0.3) 0.3 (0.1-0.6)
No ref. ref. ref. ref. 
Any polydrug use (any)  
≥ 2 drugs 2.2 (1.5-3.4) 2.0 (1.1-3.5) 0.7 (0.4-1.2) 0.7 (0.4-1.2)
Main drug only ref. ref. ref. ref. 
Table 4. (1) Odds ratio (OR) with 95% confidence intervals (95% CI) refer to primary Amphetamine-Type Stimulant (ATS) versus 
opioids (reference group). (2) Multivariable models were adjusted for age, sex, education, duration of injecting, needle/syringe 
programme (NSP), drug/substitution treatment, needles/syringes (N/S) confiscated (and living arrangements in St. 
Petersburg). Statistically significant results at the α< 0.05 are marked in bold. (3) Injecting risk in the last 4 weeks. 
 
 
 
Table 5. Associations between ATS injection and sexual risk behaviours (Kohtla-Järve, St. Petersburg) 
OUTCOMES: SEXUAL RISK (3) Kohtla-Järve - ATS injectors (n=195) St. Petersburg - ATS injectors (n=27) 
 (reference: opioid injectors) OR(1)95% CI aOR(2)95%CI OR(1)95% CI aOR(2)95%CI 
Any sex in 6 months  
Yes 1.8 (1.0-3.3) 1.7 (0.9-3.3) 1.8 (0.8-3.9) 1.6 (0.7- 3.8)
No ref. ref ref. ref 
Regular sex partner injects  
Yes 0.7 (0.4-1.1) 0.8 (0.5-1.9) 0.8 (0.2-3.3) 0.8 (0.2- 3.0)
No ref. ref ref. ref 
Casual sex partner injects  
Yes 1.1 (0.8-1.5) 1.8 (0.5-7.1) 0.5 (0.1-2.6) 0.4 (0.1-2.2)
No ref. ref ref. ref 
Was ever paid for sex   
Yes 1.3 (0.9-1.8) 2.6 (1.2-5.7) 12.2 (3.7-40) 5.2 (1.0-27)
No ref. ref ref. ref 
Multiple sex partners  
>= 2 sex partners 0.8 (0.4-1.6) 0.7 (0.3-1.5) 0.9 (0.5-1.8) 0.7 (0.3-1.6)
one sex partner Ref ref ref ref 
Condom with regular partner   
Yes (consistent) 0.9 (0.7-1.4) 1.0 (0.7-1.4) 1.9 (0.4-4.6) 1.5 (0.5-4.5)
No ref. ref ref ref 
Condom with casual partner  
Yes (consistent) 1.4 (0.6-3.0) 1.2 (0.6-2.6) 10.4 (1.9-57) 8.0 (1.1-60)
No ref. ref ref ref 
Table 5:(1) Odds ratio (OR) with 95% confidence intervals (95% CI) refer to primary Amphetamine-Type Stimulant (ATS) versus 
opioids (reference group). (2) Multivariable models were adjusted for age, sex, education, duration of injecting, needle/syringe 
programme (NSP), drug /substitution treatment, needles/syringes (N/S) confiscated (and living arrangements in St. 
Petersburg). Statistically significant results at the α< 0.05 are marked in bold. (3) Sexual risk in the last 6 months. 
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Table 6. Associations between ATS injection and serological markers (Kohtla-Järve, St. Petersburg) 
SEROLOGICAL MARKERS (3) Kohtla-Järve - ATS injectors (n=195) St. Petersburg - ATS injectors (n=27) 
(reference: opioid injectors) OR(1)95% CI aOR(2)95%CI OR(1)95% CI aOR(2)95%CI 
HIV status   
Positive 0.4 (0.3-0.6) 0.6 (0.5-0.8) 0.2 (0.1-0.4) 0.3 (0.1-0.7) 
Negative ref ref ref ref 
Hepatitis C   
HCV reactive 0.3 (0.2-0.4) 0.5 (0.3-0.6) Not collected Not collected 
Non-reactive ref. ref - - 
HSV-2 status   
Positive 1.0 (0.6-1.6) 1.2 (0.7-2.0) Not collected Not collected 
Negative ref. ref - - 
Table 6: (1) Odds ratio (OR) with 95% confidence intervals (95% CI) refer to primary Amphetamine-Type Stimulant (ATS) versus 
opioids (reference group). (2) Multivariable models were adjusted for age, sex, education, duration of injecting, needle/syringe 
programme (NSP), drug /substitution treatment, needles/syringes (N/S) confiscated (and living arrangements in St. 
Petersburg). Statistically significant results at the α< 0.05 are marked in bold. HIV= Human Immune deficiency Virus. 
HCV=Hepatitis C and HSV-2=Herpes Simplex Virus. 
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